Searched for
VIATRIS CANADA
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...- Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, BioconBiocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...
- S&P 500 ends down as Nvidia tumbles following reportS&P 500 and Nasdaq ended sharply lower on Thursday due to Nvidia's disappointing quarterly report and data indicating a cooling U.S. econom...
- S&P 500, Nasdaq fall as Nvidia swings to red, economic data disappointsThe S&P 500 and Nasdaq fell after Nvidia shares declined, despite earlier gains. Economic data showing cooling suggests a stalling U.S. eco...
- Biocon Biologics completes integration of Viatris' biosimilar business in 120 countriesThe company said over 10 emerging markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integrat...
- 'Biocon looking at options to cut debt taken for Viatris' business buy'"We are looking at a number of options to reduce that... I can say that you'll see the debt level coming down in the coming quarters," he s...
- Quite comfortable about level of debt currently on our books: Shreehas Tambe, Biocon BiologicsSo from that point of view in the sense, of course, we expect it to be neutral or maybe slightly better but more or less neutral. On the ma...
- Biocon Biologics launches biosimilar adalimumab in USAdalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...
- Trying to raise an additional $300 million to further reduce debt: Kiran Mazumdar Shaw, BioconWe are progressing well with various interested investors and we will obviously share it with you as and when we conclude these investment ...
- Will Biocon's foray into biosimilar boost its bottomline?Biological drugs are harvested from living organisms or certain components of living organisms. These drugs are very specific and highly ef...
- Market movers: LIC shareholders lose Rs 77K crore in four days; Paytm gets 4% lift ahead of Q4 showLIC stock has fallen 13 per cent from its issue price of Rs 949 to Rs 826. In that process, shareholders of the company have lost over Rs 7...
- Biocon climbs 4% as pharma giant’s arm launches cancer treatment product AbevmyBiocon’s share price climbed to a high of Rs 334.70 as against Rs 322.95 at previous close on the BSE.Abevmy is a recombinant humanized mon...
- Stocks in the news: NTPC, Wipro, HPCL, Ashok Leyland, V-Guard and ConcorNTPC, Thermax, Paytm, Zydus Lifesciences, Indigo Paints, IRFC, Pfizer, Metro Brands, Narayana Hrudayalaya, Nuvoco Vistas, Sobha, IDFC, Amaj...
- Biocon Biologics acquires Viatris' biosimilar business for $3.34 billionBBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...
- Biocon and Viatris to distribute Insulin Glargine through Walgreens in USWhile Viatris has commercialisation rights for the US, Canada, Australia, EU and others, Biocon will be able to commercialise the products ...
Load More
